Hamostaseologie
Scope & Guideline
Advancing Hematology: Unraveling the Complexities of Hemostasis
Introduction
Aims and Scopes
- Clinical Management of Hemostasis and Thrombosis:
The journal covers various aspects of clinical management, including guidelines and recommendations for treating patients with bleeding disorders, thrombosis, and other related conditions. - Research on Coagulation Mechanisms:
It provides insights into the underlying biological processes involved in coagulation and thrombosis, including studies on platelet function, clotting factors, and the impact of genetic mutations. - Innovative Therapeutic Approaches:
The journal highlights novel therapies, such as gene therapy, direct oral anticoagulants (DOACs), and other emerging treatment options for various hemostatic disorders. - Patient-Centric Studies:
Research that emphasizes the patient experience, including management strategies for specific populations (e.g., pediatric patients, cancer patients) and their unique needs in hemostasis and thrombosis. - Public Health and Policy in Hemostasis:
The journal addresses public health concerns, including the implications of hemostatic disorders on healthcare systems and policies, as well as guidelines for practice in different healthcare settings.
Trending and Emerging
- Cancer-Associated Thrombosis:
Research focusing on the relationship between cancer and thromboembolic events is on the rise, highlighting the need for specialized management strategies for this vulnerable population. - Personalized Medicine Approaches:
There is a growing emphasis on individualized therapy, particularly in the context of hemophilia and other bleeding disorders, as seen in studies exploring tailored treatment regimens based on patient-specific factors. - Impact of COVID-19 on Hemostasis:
The pandemic has spurred increased research into the effects of COVID-19 on coagulation pathways and thromboembolic complications, marking a significant shift in research priorities. - Integration of Technology in Management:
Emerging themes include the use of digital health solutions and innovative technologies for monitoring and managing hemostatic disorders, reflecting the ongoing digital transformation in healthcare. - Gene Therapy and Novel Anticoagulants:
There is a notable trend towards exploring gene therapy and new anticoagulant agents as potential game-changers in the treatment landscape for hemophilia and thrombosis.
Declining or Waning
- Traditional Laboratory Diagnostics:
There has been a noticeable decrease in papers focused on traditional diagnostic methods for coagulation disorders, likely due to the advent of more advanced and efficient testing technologies that have overshadowed older approaches. - Historical Treatments and Practices:
Topics related to older treatment modalities, such as traditional anticoagulants or outdated surgical techniques, have become less frequent as newer, evidence-based practices gain prominence in the literature. - Basic Research on Non-Hemostatic Disorders:
Research that broadly intersects with hemostasis but focuses less on direct implications for thrombosis or bleeding disorders has decreased, as the journal shifts towards more clinically relevant studies.
Similar Journals
Hematology-American Society of Hematology Education Program
Advancing Hematology through Expert EducationHematology-American Society of Hematology Education Program is a premier peer-reviewed journal dedicated to advancing the field of hematology through comprehensive educational content. Published by the American Society of Hematology, this journal plays a crucial role in disseminating knowledge to researchers, clinicians, and students in hematology and related disciplines. With an impressive Q1 status in the field, it ranks among the top journals at the forefront of hematological research, as evidenced by its 60th percentile ranking in Scopus' Medicine - Hematology category. Although it does not offer open access, the journal provides invaluable insights and educational resources from leading experts, focusing on the latest advancements, treatment protocols, and evolving understanding of blood disorders. Covering a wide range of topics, from basic research to clinical applications, this journal is essential for anyone seeking to deepen their expertise and stay informed on the latest developments in hematology. For further engagement, readers can access insightful articles published since 2001, ensuring a rich repository of knowledge for ongoing research and clinical excellence.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS
Transforming understanding of blood disorders.JOURNAL OF THROMBOSIS AND THROMBOLYSIS, published by Springer in the Netherlands, serves as a vital platform for research in the fields of Cardiology and Cardiovascular Medicine and Hematology. With an impressive impact factor, this journal ranks in the Q2 category for both fields according to the latest metrics, evidencing its significant influence and contribution to ongoing scholarly discourse. Spanning over three decades from 1994 to 2024, the journal provides an essential source for innovative studies, clinical practices, and comprehensive reviews related to thrombosis and thrombolysis. Researchers, clinicians, and students alike will find valuable insights and cutting-edge knowledge that address the complexities of blood coagulation and its implications in cardiovascular health. The journal is indexed in Scopus, with commendable rankings, further establishing its reputation in the academic community.
Journal of Hematology
Innovating Insights into Blood DisordersThe Journal of Hematology, published by ELMER PRESS INC, serves as a pivotal platform for disseminating cutting-edge research in the field of hematology. With an ISSN of 1927-1212 and an E-ISSN of 1927-1220, this journal is committed to advancing scientific knowledge and clinical practice through high-quality peer-reviewed articles encompassing all aspects of blood disorders, from basic science to health policy implications. While the journal currently operates under a traditional access model, it nonetheless prioritizes the rapid publication of significant findings, ensuring that researchers, clinicians, and students have timely access to the latest advancements in hematological research. Positioned to bridge gaps in knowledge and foster collaboration among scholars worldwide, the Journal of Hematology is an essential resource for anyone invested in this vital area of medicine.
Turkish Journal of Hematology
Championing open access to vital hematology knowledge.Turkish Journal of Hematology is an esteemed publication dedicated to advancing the field of hematology, producing influential research since its inception in 1999 under the auspices of GALENOS PUBL HOUSE. With an Open Access model, it facilitates widespread dissemination of knowledge, allowing researchers, clinicians, and students to stay abreast of the latest developments in blood disorders and treatments. With an ISSN of 1300-7777 and an E-ISSN of 1308-5263, the journal holds a commendable position in the academic community, evidenced by its 2023 Q3 ranking within the hematology category and its standing at #80 out of 137 in the Scopus database, placing it in the 41st percentile. Covering a wide scope of topics within hematology, this journal serves as a critical resource for disseminating innovative research and clinical practices pertinent to the ongoing challenges faced in this vital area of medicine. With its continuous publication until 2024, Turkish Journal of Hematology remains a beacon for enhancing the understanding and treatment of hematological conditions within the Turkish and global medical communities.
BLOOD COAGULATION & FIBRINOLYSIS
Driving Progress in Hematological TherapiesBLOOD COAGULATION & FIBRINOLYSIS, a distinguished journal in the field of hematology, is published by Lippincott Williams & Wilkins, a reputable name in academic publishing. Since its inception in 1990, this journal has been committed to advancing the understanding of blood coagulation and fibrinolysis, focusing on the molecular mechanisms, clinical implications, and therapeutic aspects of these critical processes. With an impact factor reflecting its significance within the academic community, currently ranking Q3 in both Hematology and Miscellaneous Medicine for 2023, this journal serves as a pivotal platform for researchers and professionals alike. By providing access to cutting-edge research and reviews, BLOOD COAGULATION & FIBRINOLYSIS endeavors to foster collaboration and innovation in the treatment of coagulation disorders. Interested readers can explore ongoing contributions to the field through subscriptions and institutional access options.
CURRENT OPINION IN HEMATOLOGY
Exploring the forefront of hematology research and insights.CURRENT OPINION IN HEMATOLOGY is a leading peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the latest advancements and insights in the field of hematology. With an impressive impact factor and ranked in the first quartile (Q1) of its category, this journal serves as a vital resource for researchers, clinicians, and students seeking to stay informed on contemporary issues and emerging trends in hematological research and treatment. Established in 1994, it showcases critical reviews, expert commentary, and systematic analyses across a broad spectrum of hematology topics, contributing significantly to clinical and experimental knowledge through its robust editorial standards. While offering traditional subscription access, CURRENT OPINION IN HEMATOLOGY remains committed to providing a platform that bridges the gap between fundamental research and clinical application, making it indispensable for professionals dedicated to advancing patient care and scientific understanding in hematology.
BLOOD PRESSURE
Advancing cardiovascular health through innovative research.BLOOD PRESSURE is a distinguished journal published by Taylor & Francis Ltd in the field of cardiology and internal medicine, with an ISSN of 0803-7051 and E-ISSN of 1651-1999. Since its inception in 1992, it has become a vital source of research and clinical information, dedicated to advancing our understanding of blood pressure-related health issues. With a notable categorization of Q3 in Cardiology and Cardiovascular Medicine and Q2 in Internal Medicine as of 2023, this journal exemplifies a commitment to evidence-based findings that impact clinical practice and patient care. The journal facilitates a platform for original research, reviews, and case studies, aiming to bridge the gap between researchers and practitioners. Although it does not currently offer open access, BLOOD PRESSURE remains an essential resource for professionals and students alike, striving to enhance health outcomes through dedication to innovative cardiovascular research.
HAEMOPHILIA
Pioneering insights in hematology and genetics.HAEMOPHILIA is a leading peer-reviewed journal published by Wiley, dedicated to advancing research and clinical practices in the fields of hematology and genetics. With an impressive Impact Factor and recognition within the Q1 category for Genetics (clinical), Hematology, and Medicine (miscellaneous), this journal presents a unique platform for the dissemination of high-quality research from 1995 to the present. Researchers in these dynamic fields will find invaluable insights through original articles, systematic reviews, and clinical trials, all aimed at improving therapeutic strategies and patient outcomes. Although it operates on a subscription basis, HAEMOPHILIA's commitment to excellence is reflected in its Scopus rankings, where it stands in the 74th percentile for hematology and the 71st percentile for clinical genetics. As an essential resource for academics, healthcare professionals, and students, HAEMOPHILIA plays a pivotal role in fostering innovation and collaboration within the global medical community.
BLOOD REVIEWS
Empowering research, transforming blood health.BLOOD REVIEWS is a highly regarded journal published by Churchill Livingstone, specializing in the fields of Hematology and Oncology. With an impressive Q1 ranking in both disciplines and placing in the top 10% of its peer categories according to Scopus metrics, it provides an essential platform for the dissemination of cutting-edge research and reviews pertaining to blood disorders and cancer treatment. Since its inception in 1987 and continuing through 2024, the journal has established itself as a cornerstone for healthcare professionals, researchers, and students who seek to advance their understanding of hematologic and oncologic topics. While not an open-access journal, BLOOD REVIEWS retains a reputation for delivering high-quality, peer-reviewed articles that foster dialogue and innovation within the scientific community. For those in the United States and beyond, the journal serves as a vital resource, housed at the Journal Production Department in Edinburgh, Scotland, ensuring accessibility and a global reach in its critical academic contributions.
Pneumonia
Fostering Global Collaboration in Respiratory HealthPneumonia is an esteemed open-access journal published by BMC, focusing on a comprehensive range of topics related to pneumonia and respiratory diseases. Since its inception in 2012, the journal has been dedicated to disseminating high-quality research that advances scientific understanding and clinical practices in the field. With an ISSN of 2200-6133, this journal provides researchers, healthcare professionals, and students with immediate access to groundbreaking studies, systematic reviews, and clinical guidelines that address the global challenges posed by pneumonia. By facilitating the open exchange of knowledge, Pneumonia significantly contributes to the enhancement of patient care and the development of effective treatment strategies. Situated in the heart of London, Pneumonia harnesses the strengths of the BMC platform to maintain high academic standards and reach a diverse international audience.